Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Articles by Natasha Yetman

U.S. to Announce New Warning on J&J Coronavirus Vaccine for Guillain-Barré Syndrome

Reuters Staff  |  July 12, 2021

(Reuters)—The U.S. Food & Drug Administration (FDA) is expected to announce a new warning on Johnson & Johnson’s (J&J’s) coronavirus vaccine related to a rare autoimmune disorder, The Washington Post reported on Monday, citing four people familiar with the matter.1 According to The Post, about 100 preliminary reports of Guillain-Barré syndrome have been detected in the…

Patients with Rheumatic Disease May Experience Flares after SARS-CoV-2 Vaccination

Linda Carroll  |  July 12, 2021

(Reuters Health)—Among a group of New York patients with rheumatic diseases who received a SARS-CoV-2 vaccine, nearly one in six experienced disease flares after getting their shots, a new study finds.1 A survey of more than 1,100 patients who had received at least one vaccine dose revealed that 14.9% experienced flares. Among the 654 who…

Tofacitinib Promising for COVID-19 Pneumonia

Reuters Staff  |  June 22, 2021

(Reuters)—Pfizer Inc. said on June 16 its oral rheumatoid arthritis (RA) drug Xeljanz (tofacitinib) reduced death or respiratory failure in hospitalized COVID-19 patients with pneumonia in Brazil, meeting the study’s main goal. Results of the study, which tested the drug in 289 hospitalized adult patients with the respiratory illness caused by the coronavirus, were published…

Polymyositis-Dermatomyositis Tied to Arrhythmias in Young, Middle-Aged Adults

Lisa Rapaport  |  June 22, 2021

(Reuters Health)—Young and middle-aged adults with polymyositis-dermatomyositis are more likely to have arrhythmias in general, and supraventricular arrhythmias in particular, than matched controls without these rare rheumatic conditions, a U.S. study suggests.1 Researchers examined retrospective data on adults hospitalized between 2016 and 2018, including 32,085 patients with polymyositis-dermatomyositis and 320,850 age-matched controls. Overall, both women…

Rituximab Seems Safe & Effective for Systemic Sclerosis

Marilynn Larkin  |  June 22, 2021

NEW YORK (Reuters Health)—Rituximab seemed to be a safe and effective treatment for systemic sclerosis (SSc) in a placebo-controlled validation trial in Japan.1 “A number of studies have examined B-cell depletion therapy for systemic sclerosis, and many of them have suggested that [this] is effective in treating systemic sclerosis,” Ayumi Yoshizaki, MD, tells Reuters Health…

Are Medicare Beneficiaries with Knee OA Receiving Enough Conservative Care?

Marilynn Larkin  |  June 22, 2021

NEW YORK (Reuters Health)—Non-surgical care for knee osteoarthritis (OA) is uncommon among older adults, especially in regions of the U.S. where total knee arthroplasty rates are high, a large retrospective analysis shows.1 “As rheumatologists, we often think of knee arthroplasty as the last resort, after patients have tried and failed more conservative treatments, such as…

Higher Risk of Adverse Events When Biologic Infusions Are Done at Home

By Lisa Rapaport  |  June 15, 2021

(Reuters Health)—Patients who receive biologic infusions at home may have a higher risk of adverse events than those who receive the infusions at a health care facility, a new study suggests.1 Researchers examined administrative claims data on 57,220 adults who received a total of 752,150 biologic infusions for immune-mediated disease between 2007 and 2017. The…

Add-On Voclosporin Improves Outcomes in Lupus Nephritis

David Douglas  |  June 2, 2021

NEW YORK (Reuters Health)—Voclosporin (Lupkynis) in combination with mycophenolate mofetil (MMF) and low-dose corticosteroids improves renal response rates compared with use of these agents alone in patients with in lupus nephritis, according to a company-funded study. “Lupus nephritis can be a devastating condition if not diagnosed and managed early. These data establish voclosporin as an…

New French Law Extends Benefits to Families of Healthcare Workers Who Contracted COVID-19 & Died During the Pandemic

Staff  |  June 1, 2021

According to the French newspaper, Le Monde, the French Assembly adopted the “mort pour le service de la République”—died in the service of the Republic—statute on May 27. President Emmanuel Macron says this new law is one way to support the families of personnel who die under exceptional circumstances, such as healthcare providers who died…

COVID-19 Hate Crimes Act Passed

Staff  |  June 1, 2021

On May 20, with overwhelming support from Congress, President Biden signed legislation that addresses hate crimes committed during the COVID-19 pandemic, with particular emphasis on the increase in violence against Asian Americans. The law makes reporting hate crimes easier by ensuring reporting resources are available online in multiple languages. It also authorizes grants to state…

  • « Previous Page
  • 1
  • …
  • 6
  • 7
  • 8
  • 9
  • 10
  • …
  • 97
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences